H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 42.52 HKD 1.29%
Market Cap: 257.5B HKD

Hansoh Pharmaceutical Group Company Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hansoh Pharmaceutical Group Company Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
¥4.8B
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
N/A
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Net Income (Common)
¥4.1B
CAGR 3-Years
-11%
CAGR 5-Years
-2%
CAGR 10-Years
12%
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
¥2.4B
CAGR 3-Years
-1%
CAGR 5-Years
9%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
¥7.5B
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
¥5.2B
CAGR 3-Years
25%
CAGR 5-Years
1%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
¥3.7B
CAGR 3-Years
N/A
CAGR 5-Years
244%
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.

Hansoh Pharmaceutical Group Company Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Hansoh Pharmaceutical Group Company Ltd's Net Income (Common)?
Net Income (Common)
4.8B CNY

Based on the financial report for Jun 30, 2025, Hansoh Pharmaceutical Group Company Ltd's Net Income (Common) amounts to 4.8B CNY.

What is Hansoh Pharmaceutical Group Company Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
14%

Over the last year, the Net Income (Common) growth was 1%. The average annual Net Income (Common) growth rates for Hansoh Pharmaceutical Group Company Ltd have been 21% over the past three years , 14% over the past five years .

Back to Top